Practice
Featured experience
Amazon.com $15 billion notes offering
We advised the underwriters on the offering
Circle $1.05 billion IPO
We are advising Circle on its IPO, the first IPO by a stablecoin issuer
Novartis $6 billion notes offering
We advised Novartis on the investment-grade debt offering
SailPoint $1.4 billion IPO
The shares are listed on the Nasdaq Global Select Market
Metropolis of Tokyo $1.5 billion bond offering
Davis Polk advised The Metropolis of Tokyo in connection with its $1.5 billion Rule 144A/Regulation S offering of 0.750%…
RiseSun Real Estate Development $250 million high-yield notes offering
Davis Polk advised the initial purchasers in connection with the Regulation S offering of $250 million principal amount…
Inventiva $108 million U.S. IPO and Nasdaq listing
Davis Polk advised the representatives of the underwriters in connection with an initial public offering of Inventiva S…
Centogene $49 million follow-on offering
Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting…
Oleoducto Central $500 million notes offering
Davis Polk advised the initial purchasers in connection with the offering by Oleoducto Central S.A. (OCENSA) of $500…
Revolution Medicines $179.4 million follow-on offering
Davis Polk advised the underwriters in connection with a public offering of 6,900,000 shares of common stock of…
Mizuho Financial Group $2.5 billion senior notes offering
Davis Polk advised the joint lead managers in connection with Mizuho Financial Group, Inc.’s SEC-registered takedown…
Rumo $500 million notes offering
Davis Polk advised Rumo Luxembourg S.à r.l., as issuer, and Rumo S.A., as guarantor, in connection with Rumo Luxembourg’s …
Golden Wheel Tiandi $170 million high-yield notes offering
Davis Polk advised the initial purchasers in connection with a $170 million Regulation S offering by Golden Wheel Tiandi…
Ocumension Therapeutics HK$1.55 billion IPO and HKEX listing
Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock…